Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

menu

Funding

“Defining the genetic drivers of Staphylococcus aureus corneal infections”

Role on project: Principle Investigator

Type: Research to Prevent Blindness, Career Development Award

Funding Period: January 2020-January 2024

The purpose of this award is to the define the genes and regulatory networks that enable S. aureus to establish and maintain corneal infections using whole genome sequencing coupled with in vivo transcriptomics.

“Development of Novel Ophthalmic Antibiotics”

Role on project: Principle Investigator

Type: NIH-K08, 1K08 EYE29012-01

Funding Period: May 2018- May 2023

The purpose of this mentored, clinician-scientist career development award is to provide comprehensive training in the area of antimicrobial drug discovery.  Specific goals are to conduct a large-scale chemical screen for compounds with activity against both S. aureus and P. aeruginosa biofilms, further the development of the combination polymyxin B/trimethoprim + rifampicin and to develop genetic tools in order to investigate the mechanism of action of newly identified lead compounds.

“Development of a novel class of antibiotics through identification of RNase E inhibitors”

Role on project: Co-Principle Investigator

Type: Bryant Trust

Funding Period: October 2017- October 2018

The purpose of this project is to exploit RNase E as a novel antimicrobial target in Gram-negative bacteria thorough high throughput screening strategies.

“Novel antibiotic formulations for the prevention and treatment of ocular infections”

Role on project: Co-Investigator


Type: Technology Development Award


Funding Period: January 2017-January 2018


The purpose of this funding is to facilitate the development of the combination therapy polymyxin B/trimethoprim/rifampicin for the treatment of infectious keratitis. Both in vitro formulation optimization studies will be conducted as well as in vivo work utilizing a mouse model of keratitis.

“Development of mupirocin and neomycin combination therapies for the prevention and treatment of bacterial infections”

Role on project: Co-investigator


Type: Drug Development Pilot Award, UR Ventures

Funding Period: March 2016-March 2017


The purpose of this funding is to optimize formulations of neomycin and mupirocin for the treatment of topical wound infections as well as infectious keratitis.

“Development of novel ophthalmic antibiotics”

Role on project: Principle Investigator

Type: American Society of Cataract and Refractive Surgery Foundation Research Award

Funding Period: March 2016 – March 2017

The purpose of this research is to undertake a large-scale screen of an F.D.A-approved compound library to identify agents that potentiate the activity of current ophthalmic antibiotics, thereby improving performance